Can you provide a psychiatric medication template, organized by diagnosis, for adult patients receiving methadone or buprenorphine in a medication‑assisted treatment opioid program?

Psychiatric Medication Template for MAT OTP Settings

For adult patients on methadone or buprenorphine in opioid treatment programs, psychiatric medications should be prescribed based on specific diagnoses while avoiding benzodiazepines and carefully managing other sedating agents due to respiratory depression risk. 1, 2, 3

Critical Safety Principles

Avoid concurrent benzodiazepines with methadone or buprenorphine – this combination significantly increases overdose and respiratory depression risk. 1, 3 If a patient presents already taking benzodiazepines, coordinate with psychiatry for alternative anxiolytic strategies and taper planning rather than continuing the combination.

Monitor for:

• Sedation and respiratory rate with any psychotropic addition
• QTc prolongation (methadone has higher risk than buprenorphine) 4
• Drug interactions via prescription drug monitoring programs 3

Diagnosis-Based Medication Templates

Major Depressive Disorder

First-line: SSRIs (sertraline 50-200mg, escitalopram 10-20mg, fluoxetine 20-60mg)

• Minimal drug interactions with methadone/buprenorphine
• Lower sedation risk compared to other antidepressants
• Start low, titrate slowly over 4-6 weeks

Second-line: SNRIs (venlafaxine XR 75-225mg, duloxetine 30-60mg)

• Consider if pain comorbidity present (duloxetine preferred)
• Monitor blood pressure with venlafaxine

Avoid: Tricyclic antidepressants (increase QTc risk with methadone)

Generalized Anxiety Disorder / Panic Disorder

First-line: SSRIs (same dosing as depression)

• Sertraline or escitalopram preferred
• May take 4-6 weeks for anxiolytic effect

Second-line: Buspirone 15-60mg daily (divided doses)

• Non-sedating, no abuse potential
• Requires 2-4 weeks to achieve effect
• Safe with MAT medications

Third-line: Hydroxyzine 25-100mg TID PRN

• For acute anxiety only
• Minimal abuse potential
• Monitor for sedation

Absolutely avoid: Benzodiazepines 1, 2, 3

Bipolar Disorder

Mood stabilizers:

• Lithium 600-1200mg daily (target level 0.6-1.0 mEq/L)

  • Requires regular level monitoring
  • Check renal and thyroid function

• Valproic acid 500-1500mg daily (target level 50-100 mcg/mL)

  • Monitor liver function and CBC
  • Effective for mixed episodes

• Lamotrigine 100-200mg daily

  • Slow titration required (25mg increments every 2 weeks)
  • Lower seizure risk than other anticonvulsants
  • Good for bipolar depression

Atypical antipsychotics (if needed):

• Quetiapine 300-800mg daily (sedating, use at bedtime)
• Aripiprazole 10-30mg daily (activating, use in morning)
• Olanzapine 5-20mg daily (weight gain risk)

Schizophrenia / Psychotic Disorders

First-line atypical antipsychotics:

• Risperidone 2-6mg daily
• Olanzapine 10-20mg daily
• Quetiapine 400-800mg daily
• Aripiprazole 10-30mg daily

Long-acting injectables (for adherence concerns):

• Paliperidone palmitate monthly
• Aripiprazole lauroxil monthly
• Consider earlier than in general population given OUD treatment adherence challenges

Monitor: Metabolic syndrome, extrapyramidal symptoms, prolactin elevation

Post-Traumatic Stress Disorder

First-line: SSRIs (sertraline 100-200mg, paroxetine 20-60mg)

Second-line: Prazosin 1-16mg at bedtime for nightmares

• Start 1mg, titrate by 1-2mg every 3-7 days
• Monitor blood pressure

Adjunctive: Hydroxyzine 25-50mg TID PRN for hyperarousal

Attention-Deficit/Hyperactivity Disorder

Non-stimulant first-line (preferred in OUD):

• Atomoxetine 40-100mg daily
• Bupropion XL 150-300mg daily (also helps with smoking cessation)
• Guanfacine XR 1-4mg daily

Stimulants (use with extreme caution):

• Only after documented treatment failure with non-stimulants
• Requires stable MAT (>6 months), negative UDS, psychiatric co-management
• Long-acting formulations only (methylphenidate ER, lisdexamfetamine)
• Weekly to biweekly monitoring initially

Insomnia

First-line: Sleep hygiene counseling, cognitive behavioral therapy for insomnia

Pharmacologic options:

• Trazodone 50-200mg at bedtime (sedating antidepressant)
• Mirtazapine 7.5-15mg at bedtime (also increases appetite)
• Quetiapine 25-100mg at bedtime (if mood disorder present)

Second-line:

• Gabapentin 300-900mg at bedtime
• Hydroxyzine 25-100mg at bedtime

Avoid: Benzodiazepines, zolpidem (abuse potential), diphenhydramine (anticholinergic burden)

Special Considerations for MAT Patients

Methadone-Specific Issues

• Higher QTc prolongation risk – obtain baseline and annual ECGs, especially with antipsychotics 4
• Slower metabolism – may require dose adjustments of psychiatric medications
• Split dosing may help with pain management if chronic pain present 5

Buprenorphine-Specific Issues

• Lower respiratory depression ceiling – safer with sedating psychiatric medications than methadone 4, 2
• Minimal QTc effects – less cardiac monitoring needed 4
• Can continue during psychiatric hospitalization – coordinate with inpatient team 6

Co-occurring Substance Use

• Alcohol use disorder: Naltrexone 50mg daily (compatible with buprenorphine, not methadone) 7
• Stimulant use: No FDA-approved medications; optimize psychiatric treatment, consider contingency management
• Cannabis use: Address underlying anxiety/depression rather than adding medications

Monitoring Protocol

Baseline (before starting psychiatric medications):

• ECG if prescribing methadone + antipsychotic or any QTc-prolonging agent
• Metabolic panel, liver function tests
• Pregnancy test for women of childbearing age
• Urine drug screen

Ongoing:

• Monthly visits first 3 months, then every 3 months if stable 3
• UDS at each visit to monitor for polysubstance use 3
• Side effect assessment (sedation, weight, movement disorders)
• Psychiatric symptom monitoring with validated scales
• Coordinate with MAT prescriber regarding any sedation concerns

Red Flags Requiring Immediate Consultation

• Request for benzodiazepines (offer alternatives, never prescribe) 1, 2
• Repeated positive UDS for non-prescribed substances (reassess OUD treatment adequacy) 1
• Suicidal ideation (may need higher level of psychiatric care)
• Psychotic symptoms not responding to adequate antipsychotic trial
• Severe sedation or respiratory depression (hold psychiatric medications, evaluate MAT dose)

Integration with Behavioral Health

All psychiatric medication management must occur alongside:

• Individual counseling (weekly to monthly based on stability) 7, 8
• Group therapy when available 9
• Peer support services 10
• Case management for housing, employment, social needs 6

Medication alone is insufficient – combined pharmacotherapy and cognitive behavioral therapy or other evidence-based psychotherapy improves outcomes for both OUD and psychiatric disorders. 8